Crohn’s Disease Market Size Is Expected to Grow at a CAGR of 7.6% for the Study Period of 2018–2030 by DelveInsight | Gilead Sciences, Galapagos NV, Abbvie, Roche, Genentech, Celgene, Takeda, TiGenix

Crohn’s Disease Market

DelveInsight’s ‘Crohn’s Disease Market Insights, Epidemiology, and Market Forecast – 2030’ report delivers an in-depth understanding of the Crohn’s Disease, historical and forecasted epidemiology as well as the Crohn’s Disease market trends in the United States.


Some facts of Crohn’s Disease Market are:

In the year 2020, the total prevalent case of Crohn’s Disease was 825,165 cases in the United States which are expected to grow during the forecast period, i.e., 2021–2030.
The disease epidemiology covered in the report provides historical as well as forecasted Crohn’s Disease epidemiology [segmented as Total Prevalent Cases of Crohn’s Disease, Total Diagnosed Cases of Crohn’s Disease, Age-specific cases of Crohn’s Disease, Severity-specific Cases of Crohn’s Disease, and Treated cases of Crohn’s Disease] in the United States from 2018 to 2030.
The US FDA-approved biologics for the treatment of Crohn’s Disease include infliximab, adalimumab, certolizumab, vedolizumab, natalizumab, ustekinumab.
Growth of the Crohn’s Disease market is expected to be mainly driven by the entry of novel therapies with better clinical profile and patient convenient RoA, increase in market penetration of targeted/advanced therapies, advances in research and development, new biomarkers for diagnosis of Crohn’s Disease, and increasing prevalence of Crohn’s Disease.


Request for Sample Report:


Crohn’s Disease Report Scope

The report covers the descriptive overview of Crohn’s Disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Crohn’s Disease epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Crohn’s Disease are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Crohn’s Disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Crohn’s Disease market


Request for Sample Report:


Crohn’s Disease is a type of inflammatory bowel disease (IBD). It is an inflammatory condition of the gastrointestinal tract, which most commonly affects the end of the small bowel (the ileum), the beginning of the colon, and any part of the gastrointestinal (GI) tract from the mouth to the anus. Additionally, ulcerative colitis, an IBD that causes long-lasting inflammation and ulcers (sores) in your digestive tract, is limited to the colon, also called the large intestine. CROHN’S DISEASE is characterized by skip intestinal lesions (that is, areas of inflammation interposed between normal-appearing mucosa) anywhere in the GI tract. It involves chronic, relapsing transmural inflammation that can lead to Chronic abdominal pain, diarrhea, obstruction and/or perianal lesions.


Crohn’s Disease Therapies covered:

Jyselica/Filgotinib (Gilead Sciences/Galapagos NV)
Rinvoq/Upadacitinib (AbbVie)
Etrolizumab/RG 7413 (Hoffmann-La Roche/Genentech)
Ozanimod/Zeposia (Celgene)
Skyrizi/Risankizumab (AbbVie/Boehringer Ingelheim)
Brazikumab/MEDI-2070 (Astrazeneca)
Alofisel/Darvadstrocel (Takeda/TiGenix)
Mirikizumab/LY-3074828 (Eli Lilly and Company)
RHB-104 (RedHill Biopharma)
Etrasimod/APD334 (Arena Pharmaceuticals)
Tremfya/Guselkumab (Janssen)
Deucravacitinib/BMS-986165 (Bristol-Myers Squibb)
Tesnatilimab/JNJ-64304500 (Janssen)
Sibofimloc/EB8018 (Takeda/Enterome)
BT-11 (Landos Biopharma)
UTTR1147A/RG 7880 (Genentech)
TD-1473/JNJ 8398 (Theravance Biopharma/Janssen)
JNJ-67864238/PTG 200 (Protagonist Therapeutics/Janssen)
SHR0302 (Reistone Biopharma)
Ryoncil/Remestemcel-L (Mesoblast)
Ritlecitinib/Brepocitinib (Pfizer)


Table of content

Key Insights
Executive Summary of Crohn’s Disease
Competitive Intelligence Analysis for Crohn’s Disease
Crohn’s Disease: Market Overview at a Glance
Crohn’s Disease: Disease Background and Overview
Patient Journey
Crohn’s Disease Epidemiology and Patient Population
Treatment Algorithm, Current Treatment, and Medical Practices
Unmet Needs
Key Endpoints of Crohn’s Disease Treatment
Marketed Products
Emerging Therapies
Crohn’s Disease: Seven Major Market Analysis
Attribute analysis
7MM: Market Outlook
Access and Reimbursement Overview of Crohn’s Disease
KOL Views
Market Drivers
Market Barriers
DelveInsight Capabilities
About DelveInsight


Why should you buy this report?

The report will help in developing business strategies by understanding trends shaping and driving the Crohn’s Disease market
To understand the future market competition in the Crohn’s Disease market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Crohn’s Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Crohn’s Disease market
To understand the future market competition in the Crohn’s Disease market


About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech, and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States